AfshinNDowlatiMD

Oncology • Cleveland, OH

Associate Professor of Medicine, Case West Res University

Join to view full profile

Dr. Dowlati is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dowlati's full profile

Already have an account?

Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106
Phone+1 216-844-3951

Fax+1 216-844-5759
Is this information wrong?

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1998 - 2000
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 1999
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Universite de L'Etat a Liege Faculty of MedicineClass of 1992

Certifications & Licensure

OH State Medical License 1999 - 2025
IA State Medical License 1998 - 2005
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Top MD Consumers Checkbook

Clinical Trials

SU5416 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 May 01
Completed
Phase 1
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer Start of enrollment: 1999 Apr 01
Terminated
Phase 2
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2000 May 01
Completed
Phase 2
Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer Start of enrollment: 2000 Jul 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Start of enrollment: 2001 Sep 01
Completed
Phase 1
Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 2
GW786034 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Dec 01
Completed
Phase 1
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors Start of enrollment: 2004 May 01
Terminated
Phase 1
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2004 Apr 01
Terminated
Phase 2
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Start of enrollment: 2004 Sep 01
Terminated
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2008 Jul 01
Terminated
Phase 2
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Start of enrollment: 2009 Mar 01
Completed
Phase 2
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507 Start of enrollment: 2008 Aug 01
Withdrawn
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 1
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 28
Terminated
Phase 1
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC Start of enrollment: 2013 Sep 01
Completed
Phase 1
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10
Active, not recruiting
Phase 1
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy Start of enrollment: 2015 Jun 29
Terminated
Phase 2
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Phase 2 Study of ONC201 in Neuroendocrine Tumors Start of enrollment: 2017 Aug 02
Completed
Phase 2
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC Start of enrollment: 2020 Jan 13
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Cinta Hierro, Jordi Rodon, Andreas Wicki, Martin D Forster, Sarah P Blagden, Jun Yin, Joel M Reid, Helene Muller, Natasa Cmiljanovic, Vladimir Cmiljanovic, Filip Janku...> ;Cancers. 2024 Mar 13
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
David S Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G Christensen, Josée Morin, Diane Potvin, Demiana Fal...> ;Lung Cancer. 2024 Apr 1
A Cross-Sectional Analysis of the Lung Cancer Screening Eligibility Among Cancer Survivors Who Ever Smoked.
Cullen, J., Kong, C., Wang, Q., Hsu, M., Lin, J., Wisnivesky, J., Dowlati, A.> ;Journal of General Internal Medicine. 2024 Feb 6
The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-I...
Andrew J Gross, Saad Sheikh, Michael Kharouta, Kevin Chaung, Serah Choi, Seunghee Margevicius, Pingfu Fu, Mitchell Machtay, Debora S Bruno, Afshin Dowlati, Tithi Biswas> ;Clinical Lung Cancer. 2023 Dec 1
Subjective and Objective Hearing Loss Among US Adult Cancer Survivors.
Qian Wang, Changchuan Jiang, Chi Wen, Hui Xie, Yannan Li, Yaning Zhang, Leila J Mady, Debora S Bruno, Giselle M A Dutcher, Lauren S Chiec, Afshin Dowlati, Melinda L Hs...> ;JAMA Otolaryngology-- Head & Neck Surgery. 2023 Dec 1
2 citations
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Shivaani Kummar, Lin Shen, David S Hong, Ray McDermott, Vicki L Keedy, Michela Casanova, George D Demetri, Afshin Dowlati, Soledad Gallego Melcón, Ulrik N Lassen, Serg...> ;Cancer. 2023 Dec 1
Who Are You "KITTING"? The Use of Kits to Collect Lymph Nodes During Lung Cancer Surgery.
Afshin Dowlati, Christopher W Towe, Philip A Linden> ;Journal of Thoracic Oncology. 2023 Jul 1
2 citations
Survival in elderly patients with breast cancer with and without autoimmune disease.
Demitrios Dedousis, Anastasia N Vassiliou, Shufen Cao, Deepthi Yammani, Ravi K Kyasaram, John P Shanahan, Melissa C Keinath, Melinda L Hsu, Pingfu Fu, Afshin Dowlati, ...> ;Cancer Medicine. 2023 Jun 1
10 citations
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation.
Smruthy Sivakumar, Jay A Moore, Meagan Montesion, Radwa Sharaf, Douglas I Lin, Caterina I Colón, Zoe Fleishmann, Ericka M Ebot, Justin Y Newberg, Jennifer M Mills, Pri...> ;Cancer Discovery. 2023 Jul 7
1 citations
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
Xiaofei Zhou, Debra L Richardson, Afshin Dowlati, Sanjay Goel, Solmaz Sahebjam, James Strauss, Sant Chawla, Ding Wang, Diane R Mould, Vivek Samnotra, Douglas V Faller,...> ;Clinical Pharmacology in Drug Development. 2023 Mar 1
Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review.
Reyes Bernabé-Caro, Yuanbin Chen, Afshin Dowlati, Paula Eason> ;Clinical Lung Cancer. 2023 May 1
36 citations
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Luis Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L Johnson, Neeltje St...> ;Journal of Clinical Oncology. 2023 Jun 1
Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status.
Matthew M Mirsky, Carley Mitchell, Augustine Hong, Shufen Cao, Pingfu Fu, Seunghee Margevicius, Sulin Wu, Afshin Dowlati, Ariel Nelson, J Eva Selfridge, Nikhil Ramaiya...> ;Cancer Management and Research. 2023 Jan 1
1 citations
Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
Mohammad A Shatat, Betsy Gauthier, Suzy Yoon, Eric Yuan, Peiying Yang, Goutham Narla, Afshin Dowlati, Richard T Lee> ;Cancer Medicine. 2023 Apr 1
3 citations
Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.
Gary Wildey, Ashley M Shay, Karen S McColl, Suzy Yoon, Mohammad A Shatat, Ahmad Perwez, Kyle B Spainhower, Adam M Kresak, MaryBeth Lipka, Michael Yang, Mohadese Behtaj...> ;Molecular Cancer Therapeutics. 2023 Feb 1
3 citations
A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous N...
Sarina Piha-Paul, George Simon, Chandra P Belani, Heman Chao, Kim Gaspar, Brenda Lee, Afshin Dowlati> ;JTO Clinical and Research Reports. 2022 Nov 1
2 citations
Comparing Survival in Patients With Lung Cancer With and Without a History of Common Autoimmune Disease.
Demitrios Dedousis, Anastasia N Vassiliou, Shufen Cao, Deepthi Yammani, Ravi K Kyasaram, John Shanahan, Melissa C Keinath, Melinda L Hsu, Pingfu Fu, Afshin Dowlati, Zh...> ;JTO Clinical and Research Reports. 2022 Sep 1
10 citations
Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications.
Faizan Haider Khan, Malik Johid Reza, Yusra Fatima Shao, Ahmad Perwez, Honey Zahra, Afshin Dowlati, Ata Abbas> ;Biochimica Et Biophysica Acta. Reviews on Cancer. 2022 Sep 1
4 citations
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
Afshin Dowlati, Ata Abbas, Timothy Chan, Brian Henick, Xuya Wang, Parul Doshi, Pingfu Fu, Jyoti Patel, Fengshen Kuo, Han Chang, David Balli> ;JCO Precision Oncology. 2022 Aug 1
6 citations
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced-Positive NSCLC.
Dong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, Gregory J Riely, Geoffrey R Oxnard, Tarek Mekhail, Peter Schmid, Afshin Dowlati, Rebecca S Heist, Antoinette J Woznia...> ;JTO Clinical and Research Reports. 2022 Aug 1
5 citations
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Luis Paz-Ares, David R Spigel, Yuanbin Chen, Maria Jove, Oscar Juan-Vidal, Patricia Rich, Theresa Hayes, Vanesa Gutiérrez Calderón, Reyes Bernabe Caro, Alejandro Navar...> ;Cancer. 2022 May 1
8 citations
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung can...
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, Alejandro Navarro, Oscar Juan-Vidal, Vadim Kozlov, Gil Golden, Odette Jordan, C Q Deng, Dmitriy Bentsion, Chris...> ;Lung Cancer. 2022 Apr 1
4 citations
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
James J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T Hooper, Cris Kamperschroer, Steven I Max, Allison Moreau,...> ;Frontiers in Immunology. 2022 Jan 1
118 citations
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Apar Kishor P Ganti, Billy W Loo, Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J Downey, Martin Edelma...> ;Journal of the National Comprehensive Cancer Network. 2021 Dec 1
Join now to see all

Press Mentions

Case Comprehensive Cancer Center Awarded $8.9 Million to Expand Access to Clinical TrialsMay 16th, 2019
National Comprehensive Cancer Network Awards Grants for Small Cell Lung Cancer ResearchSeptember 4th, 2023